Vor Biopharma (NASDAQ:VOR) Stock Price Up 17.8% – Still a Buy?

Vor Biopharma Inc. (NASDAQ:VOR) was up 17.8% on Thursday . The company traded as high as $20.32 and last traded at $21.6640. 288,239 shares were traded during trading, a decline of 73% from the average daily volume of 1,053,732 shares. The stock had previously closed at $18.39.

Analyst Ratings Changes

VOR has been the topic of several recent analyst reports. Wedbush boosted their target price on shares of Vor Biopharma from $15.00 to $18.00 and gave the company a “neutral” rating in a report on Thursday, May 14th. Jefferies Financial Group upgraded Vor Biopharma to a “strong-buy” rating in a report on Thursday, April 30th. HC Wainwright reissued a “buy” rating and issued a $31.00 price objective on shares of Vor Biopharma in a research report on Monday, May 18th. Weiss Ratings raised Vor Biopharma from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday. Finally, Wells Fargo & Company began coverage on Vor Biopharma in a research report on Thursday, March 19th. They set an “overweight” rating and a $30.00 target price on the stock. Two research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Vor Biopharma currently has a consensus rating of “Moderate Buy” and an average target price of $42.25.

Vor Biopharma Stock Performance

The company’s 50 day moving average is $14.93 and its 200-day moving average is $14.57.

Vor Biopharma (NASDAQ:VOR) last posted its quarterly earnings results on Monday, March 30th. The company reported $307.61 EPS for the quarter. On average, analysts predict that Vor Biopharma Inc. will post -2.51 EPS for the current year.

Insider Activity at Vor Biopharma

In other news, Director Ra Capital Management, L.P. sold 165,150 shares of the firm’s stock in a transaction dated Wednesday, April 22nd. The stock was sold at an average price of $15.77, for a total value of $2,604,415.50. Following the completion of the sale, the director directly owned 2,402,095 shares in the company, valued at $37,881,038.15. This trade represents a 6.43% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. In the last three months, insiders sold 2,742,903 shares of company stock valued at $44,672,376. Company insiders own 0.27% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in VOR. Fcpm Iii Services B.V. bought a new position in Vor Biopharma in the third quarter worth approximately $18,496,000. Frazier Life Sciences Management L.P. bought a new stake in shares of Vor Biopharma during the fourth quarter valued at approximately $33,275,000. UBS Group AG raised its position in shares of Vor Biopharma by 284.8% during the fourth quarter. UBS Group AG now owns 292,118 shares of the company’s stock worth $3,821,000 after purchasing an additional 216,209 shares during the period. NEXTBio Capital Management LP acquired a new position in shares of Vor Biopharma during the fourth quarter worth approximately $13,080,000. Finally, Findell Capital Management LLC bought a new position in shares of Vor Biopharma in the 4th quarter worth $3,021,000. 97.29% of the stock is owned by institutional investors and hedge funds.

About Vor Biopharma

Vor Biopharma, Inc is a clinical-stage biotechnology company focused on the development of next-generation, allogeneic cell therapies for patients with hematologic malignancies. The company’s proprietary platform leverages genome editing to engineer donor-derived hematopoietic stem cells (HSCs), enabling the generation of off-the-shelf therapeutic candidates designed to overcome limitations of traditional autologous and matched donor transplants. By targeting key surface antigens and reconstituting the patient’s immune system, Vor aims to deliver curative potential with reduced treatment timelines and broader patient applicability.

The lead program, VOR33, is a CD33-edited HSC product candidate being evaluated in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS).